Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026)
Damora Therapeutics (DMRA) posted Cash from Operations of 20598000.0 for Q1 2026, down 3533.0% on a QoQ basis from 600000.0 in Q4 2025, and down 744.53% year-over-year from 3195834.73 in Q1 2025.
Damora Therapeutics (DMRA) Cash from Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 20598000.0 for Q1 2026.
- Quarterly Cash from Operations fell 744.53% year-over-year to 20598000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24859000.0 (down 64.21% YoY) and the FY2025 annual result came in at 6700000.0, up 63.98% from the prior year.
- Cash from Operations was 20598000.0 for Q1 2026 at Damora Therapeutics, down from 600000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 600000.0 in Q4 2025 and bottomed at 20598000.0 in Q1 2026.
- A 5-year average of 7395882.35 and a median of 6797000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations soared 112.24% — and 2026, when it tumbled 744.53%.
- Damora Therapeutics' Cash from Operations stood at 11448000.0 in 2022, then fell by 0.13% to 11463000.0 in 2023, then soared by 57.25% to 4900000.0 in 2024, then soared by 112.24% to 600000.0 in 2025, then tumbled by 3533.0% to 20598000.0 in 2026.
- Business Quant data shows DMRA's Cash from Operations at 20598000.0 in Q1 2026, 600000.0 in Q4 2025, and 2624000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -20.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | -2.62 Mn |
| Sep 30, 2025 | -2.62 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | -4.10 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -11.46 Mn |
| Dec 31, 2023 | -11.46 Mn |